CERS6 and neoplasm: In particular, whereas the CerS6 overexpression, which significantly increased the C16:0-Cer content, was capable of inhibiting the cell migration of two mesenchymal human BC cells (i.e., MDA-MB-231 and MDA-MB-468 cells) by the reduction of the plasma membrane fluidity, the CerS6 downregulation in two epithelial tumor cells (i.e., MCF-7 and T47D cells), which was associated with the reduction of C16:0-Cer, increased basal and CD95-mediated plasma membrane fluidity and cell migration [45].